- Monday, April 13, 2026
- India +91 7982732466
- U.S +1 217 953 4020
- Info@Shingetsuresearch.com
Global Biosimilars Market- By Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), By Manufacturing (In-house, Contract), By Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease)and By Region (North America, Europe, Asia Pacific, South America, Middle East, & Africa)- Global forecast from 2022-2030.
Global Biosimilars market Overview
The global biosimilar market is estimated to reach USD 83.7 billion by 2030, growing at a CAGR of 19.1% during the forecast period of 2022-2030. It was valued at USD 32.5 billion in 2022. Biosimilars refer to a generic product with the same active ingredients as the original drug, with no significant differences in dosage, dosage form, route of administration, safety and effectiveness, quality, therapeutic effect, and indication. It has substantial economic and social benefits such as reducing medical expenditures, improving access to medicines, and improving medical services.Global Biosimilars market Insights
Driven by pharmaceutical companies, the global biosimilar market is in a fast-growing stage. The growth rate of biosimilars is much higher than that of first research biosimilars; thus, the market size will continue to maintain a rapid growth trend. The rising treatment penetration, cost-effectiveness, and faster approval of biosimilars are deriving market growth.Furthermore, the increase in the world’s total population, aging population, rising health awareness, and the change in the spectrum of diseases have made humans pay more and more attention to life and health. Continuous improvement of medical security systems, along with growing urbanization across various countries, is promoting the demand for biosimilars. Additionally, the expansion of the biosimilar market due to the expiry of patent medicines is the major driving forces for the growth of global pharmaceutical spending. Biosimilar drugs have the same active ingredients, dosage forms, routes of administration, and therapeutic effects as the original drugs, but the prices of biosimilars are relatively low, thus have significant economic and social benefits, which lead to reduced medical expenditures, improving drug accessibility, and medical service levels.Growth Driver
Biosimilar treatment penetration increased
The demand for biosimilars continues to increase; the penetration rate of biopharmaceutical treatments has proliferated. Due to the advantages of better efficacy and lower side effects, biosimilars are rapidly growing in the field of immunological diseases and tumor treatment.Cost effectiveness of biosimilars
Biosimilars are cost-effective as they replace the original drugs, and they continue to expand new market space. The cost of research and development of biosimilar drugs is only 1/4 of the original pill, and there is ample space for the price reduction. The research and development of innovative research biomedicine takes an average of 6-15 years and costs about 350-800 million US dollars. The development of biosimilars takes an average of 6-10 years and costs the US $ 120-200 million. Thus, biosimilar drugs have distinct price advantages, and further replacement of original research drugs is an inevitable trend in the future.By Product Segmental Analysis
Based on the product, the global biosimilars market segmented into Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin. The interferon segment has dominated the market of global biosimilars. With the advent of an aging society and people’s pursuit of chronic disease treatment and health, the demand for preventive medication such as vaccines and other biological products will be favorable. The burden of chronic diseases is rising, and the annual growth of anti-tumor drugs, diabetic drugs, arthritis drugs, antiviral drugs, vaccines, and other fields will be higher than the average growth level of the world drug market.By Manufacturing Segmental Analysis
Based on the manufacturing, the global biosimilars market bifurcated into In-house, Contract. The in-house segment has bolstered the market share for the global Green biosimilars market. In-house production of biosimilars will helps in reducing the costs of overheads, delivery, and shipment. Also, in-house manufacturing will allow flexibility in operations and provide financial support with small manufactures of the biosimilar. A contract with the research development will help in saving money from overheads. Moreover, it will also improve accessibility and monitor every step of production.By Indication segmental Analysis
Based on the indication, the global biosimilars market segmented into Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease. The oncology segment will propel the market demand for the global biosimilar market. In the wake of the reduction of cost and fuel, the development of new treatment in the patient will help in fueling the demand for the global biosimilars market. As biosimilars are not a generic drug, it is highly similar to the active biological ingredients, but are less expensive. Thus, oncology will help in fueling the demand for the global biosimilars market.Region Segmental Analysis
Based on geography, the global biosimilars market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The European region has dominated the demand for biosimilars in the global market. Owing to rising chronic diseases, the geriatric population will surge the need for the biosimilars market in the forecast period from 2022-2o30. Moreover, Asia Pacific will also emerge in the biosimilar market as with increasing disposable income, the government is investing in more and more research development for developing low-cost therapeutics and treatments to reduce the cases of breast cancer, and other chronic diseases.Competitor Analysis
Companies such Pfizer, Sandoz, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy’s Laboratories, Amgen, Celltrion, Samsung Biologics, Amega Biotech, mAbxience, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, and Stada Arzneimittel AG and others are key players in the global biosimilars market.Key Stakeholders
- Market research and consulting firms
- Industry associations
- Global Biosimilars manufacturing companies
- Research organizations and consulting companies
- Organizations, associations, and alliances related to Biosimilars
- Regulatory bodies
Scope of the report
| Report Attribute | Details |
|---|---|
| Market size value in 2020 | USD 13.54 billion |
| Revenue forecast in 2027 | USD 59.27 billion |
| Growth Rate | CAGR of 23.7% from 2020 to 2027 |
| Historical data | 2017-2019 |
| Forecast period | 2021 – 2027 |
| Region covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Key companies Profiled | Pfizer, Sandoz, Dr. Reddy’s Laboratories, Amgen, Celltrion, Samsung Biologics, Amega Biotech, mAbxience, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Gedeon Richter, Biocad, Coherus Bioscience, and Stada Arzneimittel AG and others |
Recent Developments
- In May 2022, Amneal Pharmaceuticals, Inc. received United States Food and Drug Administration (“FDA”) clearance for a Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta.
- In September 2021, Samsung Bioepis released positive 5-Year Follow-up results for Trastuzumab Biosimilar.
- In September 2021, Sandoz signed a commercialization pact for biosimilar BAT1706 with Bio-Thera solutions to treat multiple types of cancers.
- In August 2021, Cipla entered into a joint venture agreement Kemwell Biopharma has to develop, manufacture and commercialize biosimilars for global markets.
The objective of the Research
- Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
- Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
- Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
- Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics.
- The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.
Market Modelling
By Product- Insulin
- Interferon
- Etanercept
- Infliximab
- Rituximab
- Glucagon
- Calcitonin
- In-house
- Contract
- Oncology
- Chronic Disease
- Blood Disorder
- Autoimmune Disease
- Europe
- North America
- Asia Pacific
- South America
- Middle East & Africa
More Related Reports:
Respiratory Care Device Market
In Silico Drug Discovery Market
Report Content
- Research Strategic Development
1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation
- Research Methodology
2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation
- Executive Summary
- Market Insights
4.1. Supply Chain Analysis
4.2. Economic Factor Analysis
4.2.1. Drivers
4.2.2. Trends
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Competitors & Product Analysis
4.5. Regulatory Framework
4.6. Company market share analysis, 2022
4.7. Porter’s Five forces analysis
4.8. Price point analysis
4.9. New Investment Analysis
4.10. PESTEL Analysis
- Global Biosimilars Market Overview
5.1. Market Size & Forecast,2017-2030
5.1.1. Demand
5.1.1.1. By Value (USD Billion)
5.2. Market Share & Forecast, 2017-2030
5.2.1. By Product
5.2.1.1. Insulin
5.2.1.2. Interferon
5.2.1.3. Etanercept
5.2.1.4. Infliximab
5.2.1.5. Rituximab
5.2.1.6. Glucagon
5.2.1.7. Calcitonin
5.2.2. By Manufacturing
5.2.2.1. In-house
5.2.2.2. Contract
5.2.3. By Indication
5.2.3.1. Oncology
5.2.3.2. Chronic Disease
5.2.3.3. Blood Disorder
5.2.3.4. Autoimmune Disease
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia-Pacific
5.2.4.4. South America
5.2.4.5. The Middle East & Africa
- North America Biosimilars Market Overview
6.1. North America Biosimilars Market Size & Forecast,2017-2030
6.1.1. Demand
6.1.1.1. By Value (USD Billion)
6.2. Market Share & Forecast, 2017-2030
6.2.1. By Product
6.2.1.1. Insulin
6.2.1.2. Interferon
6.2.1.3. Etanercept
6.2.1.4. Infliximab
6.2.1.5. Rituximab
6.2.1.6. Glucagon
6.2.1.7. Calcitonin
6.2.2. By Manufacturing
6.2.2.1. In-house
6.2.2.2. Contract
6.2.3. By Indication
6.2.3.1. Oncology
6.2.3.2. Chronic Disease
6.2.3.3. Blood Disorder
6.2.3.4. Autoimmune Disease
6.2.4. By Country
6.2.4.1. US
6.2.4.2. Canada
6.2.4.3. Mexico
6.2.5. Company Market Share (Top 3-5)
6.2.6. Economic Impact Study on North America Biosimilars Market
- Europe Biosimilars Market Overview
7.1. Europe Biosimilars Market Size & Forecast,2017-2030
7.1.1. Demand
7.1.1.1. By Value (USD Billion)
7.2. Market Share & Forecast, 2017-2030
7.2.1. By Product
7.2.1.1. Insulin
7.2.1.2. Interferon
7.2.1.3. Etanercept
7.2.1.4. Infliximab
7.2.1.5. Rituximab
7.2.1.6. Glucagon
7.2.1.7. Calcitonin
7.2.2. By Manufacturing
7.2.2.1. In-house
7.2.2.2. Contract
7.2.3. By Indication
7.2.3.1. Oncology
7.2.3.2. Chronic Disease
7.2.3.3. Blood Disorder
7.2.3.4. Autoimmune Disease
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. UK
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Rest of Europe
7.2.5. Company Market Share (Top 3-5)
7.2.6. Economic Impact Study on Europe Biosimilars Market
- Asia-Pacific Biosimilars Market Overview
8.1. Asia-Pacific Biosimilars Market Size & Forecast,2017-2030
8.1.1. Demand
8.1.1.1. By Value (USD Billion)
8.2. Market Share & Forecast, 2017-2030
8.2.1. By Product
8.2.1.1. Insulin
8.2.1.2. Interferon
8.2.1.3. Etanercept
8.2.1.4. Infliximab
8.2.1.5. Rituximab
8.2.1.6. Glucagon
8.2.1.7. Calcitonin
8.2.2. By Manufacturing
8.2.2.1. In-house
8.2.2.2. Contract
8.2.3. By Indication
8.2.3.1. Oncology
8.2.3.2. Chronic Disease
8.2.3.3. Blood Disorder
8.2.3.4. Autoimmune Disease
8.2.4. By Country
8.2.4.1. India
8.2.4.2. Japan
8.2.4.3. Australia
8.2.4.4. Rest of Asia Pacific
8.2.5. Company Market Share (Top 3-5)
8.2.6. Economic Impact Study on Asia Pacific Biosimilars Market
- South America Biosimilars Market Overview
9.1. South America Biosimilars Market Size & Forecast,2017-2030
9.1.1. Demand
9.1.1.1. By Value (USD Billion)
9.2. Market Share & Forecast, 2017-2030
9.2.1. By Product
9.2.1.1. Insulin
9.2.1.2. Interferon
9.2.1.3. Etanercept
9.2.1.4. Infliximab
9.2.1.5. Rituximab
9.2.1.6. Glucagon
9.2.1.7. Calcitonin
9.2.2. By Manufacturing
9.2.2.1. In-house
9.2.2.2. Contract
9.2.3. By Indication
9.2.3.1. Oncology
9.2.3.2. Chronic Disease
9.2.3.3. Blood Disorder
9.2.3.4. Autoimmune Disease
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
9.2.4.3. Rest of South America
9.2.5. Company Market Share (Top 3-5)
9.2.6. Economic Impact Study on South America Biosimilars Market
- The Middle East & Africa Biosimilars Market Overview
10.1. The Middle East & Africa Biosimilars Market Size & Forecast,2017-2030
10.1.1. Demand
10.1.1.1. By Value (USD Billion)
10.2. Market Share & Forecast, 2017-2030
10.2.1. By Product
10.2.1.1. Insulin
10.2.1.2. Interferon
10.2.1.3. Etanercept
10.2.1.4. Infliximab
10.2.1.5. Rituximab
10.2.1.6. Glucagon
10.2.1.7. Calcitonin
10.2.2. By Manufacturing
10.2.2.1. In-house
10.2.2.2. Contract
10.2.3. By Indication
10.2.3.1. Oncology
10.2.3.2. Chronic Disease
10.2.3.3. Blood Disorder
10.2.3.4. Autoimmune Disease
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of the Middle East & Africa
10.2.5. Company Market Share (Top 3-5)
10.2.6. Economic Impact Study on Middle East & Africa Biosimilars Market
- Competitor Analysis
11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Sandoz
11.7.2. Biocon
11.7.3. Fresenius Kabi AG
11.7.4. Boehringer Ingelheim
11.7.5. Mylan
11.7.6. Eli Lilly
11.7.7. Teva Pharmaceutical
11.7.8. Reddy’s Laboratories
11.7.9. Amgen
11.7.10. Celltrion
11.7.11. Samsung Biologics
11.7.12. Amega Biotech
11.7.13. mAbxience
11.7.14. Probiomed
11.7.15. Apotex
11.7.16. Gedeon Richter
11.7.17. Biocad
11.7.18. Coherus Bioscience
11.7.19. Stada Arzneimittel AG
11.7.20. Other Prominent Players
Frequently Asked Questions (FAQ):
Biosimilars refer to a generic product that is very close in structure and function to a biological drug.
Riabni, Hulio, Nyvepria, Avsola, Semglee, etc., are examples of biosimilars.
The global biosimilar market is estimated to reach USD 83.7 billion by 2030, and It was valued at USD 32.5 billion in 2022.
The growth rate of the Global Biosimilars market is 19.1% during the forecast period.
The Cost-effectiveness of biosimilars and increase in Biosimilar treatment penetration are the growth drivers of the Global Biosimilars market.
